Occam Global is an international executive recruiting and leadership advisory firm specializing in building management teams for innovative companies in the life sciences, AI, robotics, defense, technology, and venture capital sectors.
The firm’s unique competence lies in a proven ability to attract exceptional business and scientific leaders, fluid access to uncommon talent, and an enduring commitment to results informed by elevated ethics and enlightened aggression.
As a result, Occam has established itself as a leading search partner for entrepreneurs, investors, and corporations globally. Our success is rooted in cultivating and valuing relationships, establishing trust with entrepreneurs, executives, and investors, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.
Each in our own fashion, we sat in the mud in 2012. I had just retired from a 25-year career at Fidelity Investments and moved from Boston to New York. John had just completed his MBA without much of a clue as to how to build his career anew after having toiled for a decade on Wall Street.
With common resolution, an intergenerational conspiracy was hatched, one which allowed us to reinvent ourselves. We reached for the stars in creating a family business. I would find a new creative platform to ply a trade honed over three decades in Boston and John would get a fresh start in a business which he had witnessed me practice throughout his youth.
Thus, Occam was born. A fusion of hard-earned wisdom and amorphous creative vigor. Our collaboration has yielded a richly successful global search firm, one dedicated to helping entrepreneurs realize their vision. Occam’s culture is rooted in intuitive team play, mutual respect, warmth of spirit, uncompromising ethics and clarity of purpose – family values.
We built our firm on the pillars of objectivity, undiluted ethics, and enlightened aggression.
With a process that’s rooted in relationships, data, and intellect, we’ve provided professional judgments that have made a lasting impact on our partners.
Our judgements are simultaneously inspired by instinct and pragmatism, resulting in balanced outcomes designed to endure.
New York City-based executive search firm Occam Global has recruited Natalie Holles as CEO of NASDAQ-traded Aura Biosciences in Boston, MA. She succeeds Elisabet de los Pinos, the company’s founder, who stepped down from her roles as CEO and president and member of the board of directors on the same date. “We are delighted to welcome Natalie as CEO
New York City-based executive search firm Occam Global has placed Marcus Schindler as a member of the advisory board at Cradle, the enterprise-grade AI platform for protein engineering. He will help accelerate the platform’s scientific impact and drive broader adoption of AI-powered protein engineering across the life sciences industry. “Marcus is renowned for modernizing drug discovery at some
New York City-based executive search firm Occam Global has recruited Craig T. Basson as chief medical officer and president of R&D of Variant Bio, a genomics-driven AI drug discovery company in Seattle, WA. “Craig’s career uniquely spans deep human genetics, rigorous clinical science, and successful drug development at scale,” said Andrew Farnum, chief executive officer of Variant Bio. “His
New York City-based executive search firm Occam Global has recruited Chris Boulton as the new CEO of Prolynx. “We engineered this platform to enable medicines that were previously impossible to make,” said Daniel Santi, co-founder of Prolynx. “Having established the viability and versatility of our technology in earlier clinical applications, we have now optimized it to specifically address
In May 2026, Occam Global placed Natalie Holles as CEO of Aura Biosciences (NASDAQ: AURA). Natalie is a proven biopharma CEO with a track record of building and leading innovative companies through critical inflection points. Most recently, she served as President and CEO of Third Harmonic Bio, where she guided the company through its IPO and advanced its clinical pipeline. Prior to
In March 2026, Occam placed Athena Countouriotis, MD, on the Board of Directors of Umoja Biopharma and Andrew C. Chan, MD, PhD, on Umoja’s Scientific Advisory Board. Countouriotis is Co-Founder, President, and CEO of Avenzo Therapeutics and previously led Turning Point Therapeutics through its IPO and $4.1 billion acquisition by Bristol Myers Squibb in 2022. Her career spanssenior R&D and executive roles
In March 2026, Occam Global, a leader in executive recruiting for TechBio, appointed Marcus Schindler, PhD, to Cradle’s Advisory Board. Cradle is an AI-powered protein engineering company accelerating innovation across the life sciences. Schindler most recently served as Executive Vice President and Chief Scientific Officer at Novo Nordisk, where he led global research and early development across major therapeutic
NEW YORK, Jan. 21, 2026 — Occam Global, a leading executive search and advisory firm to life science innovators, announced today the successful placement of Craig T. Basson, MD, PhD, as CMO and President of R&D at Variant Bio, a genomics-driven AI drug discovery company. Basson brings more than 25 years of leadership experience across academic medicine, global pharmaceutical development,
Case Studies
Read about how Occam Global is helping innovative organizations tackle their biggest executive recruitment challenges
Blog & Insights
Discover new tips, industry news and guides by Occam Global
-Latest Interview: Whit Bernard, CEO of Metsera